Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 173

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 173
---
 to transactions in which we have engaged in the past. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.

Cash Flows

Cash flows are comprised of the following (dollars in thousands):Nine Months EndedSeptember 30,Change20252024AmountNet cash provided by (used in): Operating activities $27,470 $127,545 $(100,075)Investing activities 55,416 (177,229)232,645 Financing activities 604 6,303 (5,699)Net change in cash and cash equivalents83,490 (43,381)126,871 Cash and cash equivalents at beginning of year69,331 75,054 (5,723)Cash, cash equivalents, and restricted cash at end of period$152,821 $31,673 $121,148 

Operating Activities

Net cash provided by operating activities was $27.5 million compared to $127.5 million for the nine months ended September 30, 2025, and 2024, respectively. The decrease in cash flows provided by operating activities is primarily due to the decrease in net earnings as well as changes in working capital. The Company reported net loss of $34.4 million and net earnings of $58.5 million for the nine months ended September 30, 2025 and and 2024, respectively. The decline in earnings is principally due to $70.9 million acquisition-related costs incurred related to the to the Sage Acquisition in July 2025. 

Investing Activities

Net cash provided by investing activities was $55.4 million for the nine months ended September 30, 2025 compared to net cash used in investing activities of $177.2 million during the same period in 2024. The change was primarily due to the following:

•Cash outflows related to the Sage Acquisition in 2025 (net of cash acquired) of $293.1 million.

•Net cash inflows from marketable securities activity were higher in 2025 compared to the same period in 2024 due to maturities of the marketable securities, whereby the proceeds were used to fund the Sage Acquisition in 2025.

50

Financing Activities

Net cash provided by financing activities was $0.6 million for the nine months ended September 30, 2025 compared to $6.3 million provided by during the same period in 202